Evaluation of Panchkol Churna against lifestyle modification in cardiovascular risk management: a protocol for an open-label, randomized comparative clinical trial
DOI:
https://doi.org/10.18203/2349-3259.ijct20261387Keywords:
Ayurveda, Cardiovascular disease, Gene expression, Panchkol churnaAbstract
Background: Cardiovascular disease (CVD) remains the leading cause of global mortality, with significant variations in prevalence and mortality rates. Ayurveda advocates the Rasadhatu dushti (RDD) as a component in the development of Hrid rogas. Also, Hridaya has been described as the root (Moola) of Rasavaha srotas, therefore any kind of vitiation in Rasadhatu is liable to affect the heart causing pathologies. The study aims to provide evidence for the role of RDD in CVD and explore integrative approaches to reduce the risk of CVDs.
Methods: This is a study with two phases including a screening and recruitment phase to assess prevalence of RDD with sample size of 390 participants and a clinical trial phase with two groups (A & B) with 30 participants in each group. The participants in group-A will receive Panchkol churna in dose of 3gm for 30 days with Luke warm before meal and group-B will receive life style modification for 30 days. The primary outcome is the assessment of prevalence of RDD in participants at risk of CVDs. The secondary outcome is the changes in Gene expression (Apo-E and IL-6), Framingham risk score (Appendix 2), RAS-RCVD (Appendix 1) score and lipid profile.
Conclusions: This protocol outlines a mixed-method study to investigate the prevalence of RDD in participants at risk of CVD and evaluate the comparative efficacy of Panchkol Churna against lifestyle modification (LSM) as risk reduction measures. The study integrates Ayurvedic concepts with modern clinical markers, such as inflammatory markers (IL-6) and gene expression (Apo-E).
Trail Registration: Clinical Trial Registry of India (CTRI/2023/05/053143).
References
Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019. J Am Coll Cardiol. 2020;76(25):2982-3021. DOI: https://doi.org/10.1016/j.jacc.2020.11.021
Davidson D. An Introduction to Cardiovascular Disease. In: Cardiovascular Disease. Springer, Boston, MA; 1994:3-19. DOI: https://doi.org/10.1007/978-1-4899-2572-5_1
Susruta. Susruta Samhita, Uttara-tantra 43/4. Nibandha Samgraha commentary by Dalhana. Varanasi: Chaukhamba Sanskrit Sansthan.
Charaka. Charaka Samhita, Sutra Sthana 23/3-7. Ayurveda Dipika commentary by Chakrapani. Varanasi: Chaukhamba Sanskrit Sansthan.
Radhika Rani RK, John KG, John FJ. Assessment of the symptomatology of Hrdroga in coronary artery disease- An observational study. Aryavaidyan. 2011;24(3):163-7.
Kolber MR, Scrimshaw C. Family history of cardiovascular disease. Can Fam Physician. 2014;60(11):1016.
Hajar R. Genetics in cardiovascular disease. Heart Views. 2020;21(1):55-6. DOI: https://doi.org/10.4103/HEARTVIEWS.HEARTVIEWS_140_19
Lloyd-Jones DM, Nam BH, D'Agostino RB Sr, Levy D, Murabito JM, Wang TJ, et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: A prospective study of parents and offspring. JAMA. 2004;291(18):2204-11. DOI: https://doi.org/10.1001/jama.291.18.2204
Susruta. Susruta Samhita, Uttar Tantra, Hridrogpratishedhiya, 46/4. Available at: https://niimh.nic.in/ebooks/esushruta/?mod=read. Accessed on 02 January 2026.
Charaka. Charaka Samhita, Sutra Sthana, Santarpaniya Adhyaya, 23/6. Available at: https://niimh.nic.in/ebooks/ecaraka/?mod=read. Accessed on 02 January 2026.
Susruta. Susruta Samhita, Sutra Sthana, Doshadhatumalakshayavriddhi Vigyaniya, 15/32. Available at: https://niimh.nic.in/ebooks/esushruta/?mod=read. Accessed on 02 January 2026.
Charaka. Charaka Samhita, Sutra Sthana, Vividhashitapitiya Adhyaya 28/9-10. Available at: https://niimh.nic.in/ebooks/ecaraka/?mod=read. Accessed on 02 January 2026.
Rani RKR, Shajahan MA. Validation of the Ayurvedic construct, Rasadhatudushti, in adults at risk of cardiovascular diseases - A mixed-method study. J Ayurveda Integr Med. 2022;13(3):100627. DOI: https://doi.org/10.1016/j.jaim.2022.100627
Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-47. DOI: https://doi.org/10.1161/01.CIR.97.18.1837
Pt. Sharangadhara. Sharangadhara Samhita, with the commentary of Adhamalla’s Dipika and Kashiram’s Gudharth-Dipika. 4th ed. Varanasi: Chaukhamba Orientalia; 2000:180.
Joehanes R, Ying S, Huan T, Johnson AD, Raghavachari N, Wang R, et al. Gene expression signatures of coronary heart disease. Arterioscler Thromb Vasc Biol. 2013;33(6):1418-26. DOI: https://doi.org/10.1161/ATVBAHA.112.301169
Cambien F, Tiret L. Genetics of cardiovascular diseases. Circulation. 2007;116(15):1714-24. DOI: https://doi.org/10.1161/CIRCULATIONAHA.106.661751
Devaraj S, Semaan JR, Jialal I. Biochemistry, Apolipoprotein B. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022. Available at: https://www.ncbi.nlm.nih.gov/books/NBK538139. Accessed on 02 January 2026.
Joshi YG. Charak Samhita of Acharya Charaka, Chikitsa sthana, Grahanidoshachikitsa. Chapter 15, verse 36. Vaidyanath Prakashana; 2014:353.
Wasnik S, Goje S, Vaidya S. Perspective of inflammation through ancient and modern parlance. Int J Ayurveda Pharma Res. 2017;5(3):151-5.
Sharma N, Yadav C, Meena M. Concept of free radical theory in Ayurveda. J Biol Sci Opin. 2015;3(1):36-8.
Catapano AL, Pirillo A, Norata GD. Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials. Br J Pharmacol. 2017;174(22):3973-85. DOI: https://doi.org/10.1111/bph.13805
Patterson CC, Smith AE, Yarnell JWG, Rumley A, Ben-Shlomo Y, Lowe GDO. The associations of interleukin-6 (IL-6) and downstream inflammatory markers with risk of cardiovascular disease: The Caerphilly Study. Atherosclerosis. 2010;209(2):551-7. DOI: https://doi.org/10.1016/j.atherosclerosis.2009.09.030
Papaioannou I, Simons JP, Owen JS. Targeted in situ gene correction of dysfunctional APOE alleles to produce atheroprotective plasma apoE3 protein. Cardiol Res Pract. 2012;2012:148796. DOI: https://doi.org/10.1155/2012/148796
Bos MM, Noordam R, Blauw GJ, Slagboom PE, Rensen PCN, van Heemst D. The ApoE ε4 isoform: can the risk of diseases be reduced by environmental factors? J Gerontol A Biol Sci Med Sci. 2019;74(1):99-107. DOI: https://doi.org/10.1093/gerona/gly226
De Lima Pizzico F, Máximo RB, Hirata MH, Ferreira GM. Mapping the APOE structurally on missense variants in elderly Brazilians. J Biomol Struct Dyn. 2024:1-9. DOI: https://doi.org/10.1080/07391102.2024.2328743
D’Agostino RB Sr, Pencina MJ, Massaro JM, Coady S. Cardiovascular disease risk assessment: insights from Framingham. Glob Heart. 2013;8(1):11-23. DOI: https://doi.org/10.1016/j.gheart.2013.01.001
Khair NH, Cyriac KS, Abdullah NT. Assessment of the risk factors in clinical cardiovascular events using Framingham Risk Score. Glob J Med Res. 2018;18(5):10-8.
Downloads
Published
How to Cite
Issue
Section
